Trials / Completed
CompletedNCT06355219
Macrovascular and Microvascular Morbidity and Mortality After Metabolic Surgery Versus Medicines
Macrovascular and Microvascular Outcomes in Patients With Type 2 Diabetes and Obesity: Comparison of Metabolic Surgery Versus GLP-1 Receptor Agonists
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 3,932 (actual)
- Sponsor
- Ali Aminian · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to compare the impact of metabolic surgery and a class of anti-diabetes medications (Glucagon-like peptide-1 receptor agonists,GLP-1 RAs) on occurrence of diseases involving small and large vessels such as heart disease, kidney disease, and disease of the retina (a part of the eye), as well as deaths.
Conditions
- Type 2 Diabetes Mellitus
- Obesity
- Microvascular Disease
- Macrovascular Disease
- Major Adverse Cardiovascular Events
- Nephropathy
- Retinopathy
- Heart Failure
- All Cause Mortality
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2022-12-31
- Completion
- 2024-05-20
- First posted
- 2024-04-09
- Last updated
- 2024-05-21
Source: ClinicalTrials.gov record NCT06355219. Inclusion in this directory is not an endorsement.